EN DE

Suzhou Iron Technology CO.,LTD. (688329) Fair Value & Analysis

Healthcare · CN · Market cap 1.7B CNY

SI Suzhou Iron Technology CO.,LTD. 688329 · SHG
Price¥19.99
Fair Value¥5.26
Upside-73.7%
Quality66/100
Watch Suzhou Iron Technology CO.,LTD. for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 2.3% net margin
Low debt · generates free cash flow
Trails peers (3/13)
Narrow moat 22/100
Evidence: High Range ¥3.68 – ¥5.34 Share as image

Fair value as of: Jul 12, 2026

From 25 valuation models · updated 30 days ago

Fair value updated Jul 12, 2026, revised from ¥5.38 to ¥5.26 (−2.2%) since Jun 24, 2026. Share price −2.7% over the past month.

A solid business, but screening 74% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (¥5.34). The favourable scenario is already priced in.
  • Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

¥76.74 ¥11.86 Fair Value ¥5.26 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.

How to read this chart

60‑month range ¥11.86 – ¥76.74 · fair‑value band ¥3.68 – ¥5.34 · the ¥19.99 price screens above the ¥5.26 fair value. Dashed = 300-day average. As of Jul 12, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Suzhou Iron Technology CO.,LTD. (688329) currently trades at ¥19.99, while our model-based Fair Value estimate is ¥5.26, implying the stock looks roughly 73.7% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Suzhou Iron Technology CO.,LTD. generated revenue of 427M CNY at a net margin of 2.3%. Revenue declined 26.0% year over year. It earns a return on equity of 1.3%. Net debt stands at 52.4M CNY. Fundamentals as of Jul 12, 2026

Our scenario range runs from ¥3.68 (bear case) to ¥5.34 (bull case); at ¥19.99, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -74%, 688329 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF ¥11.09 ¥17.78 ¥27.79 80
Residual Income ¥6.79 ¥6.36 ¥4.75 76
Rev-Margin DCF ¥6.07 ¥8.37 ¥11.49 74
All 25 models by family
DCF Models
FCF DCF ¥11.35 ¥19.24 ¥32.00 38
5Y Revenue Exit ¥6.07 ¥8.29 ¥11.04 39
5Y EBITDA Exit ¥8.83 ¥14.21 ¥20.99 41
5Y P/E Exit ¥7.20 ¥10.72 ¥14.70 38
10Y Revenue Exit ¥7.89 ¥10.67 ¥14.56 36
10Y EBITDA Exit ¥9.65 ¥14.72 ¥22.46 37
10Y P/E Exit ¥8.65 ¥12.33 ¥17.47 35
Earnings-Based
Graham-Dodd ¥1.66 ¥8.81 ¥12.20 54
Lynch FV ¥2.43 ¥3.47 ¥4.51 50
PEG = 1.0 ¥2.43 ¥3.47 ¥4.51 46
EPV ¥2.71 ¥2.92 ¥3.10 59
Dividend Discount
Gordon GGM ¥0.6900 ¥1.24 ¥1.71 70
DDM Multi-Stage ¥0.6900 ¥1.13 ¥1.32 61
Multiples
P/E Multiple ¥4.04 ¥5.38 ¥6.73 63
P/S Multiple ¥3.12 ¥4.16 ¥5.20 58
P/B Multiple ¥3.12 ¥4.16 ¥5.20 55
EV/EBIT ¥3.92 ¥4.84 ¥5.77 53
EV/EBITDA ¥7.93 ¥10.19 ¥12.46 54
EV/Revenue ¥3.12 ¥3.97 ¥4.82 43
Asset-Based
NCAV (Graham) ¥5.07 ¥6.79 ¥10.13 50
Growth DCF
Growth DCF ¥11.09 ¥17.78 ¥27.79 80
Rev-Margin DCF ¥6.07 ¥8.37 ¥11.49 74
Economic Profit
Residual Income ¥6.79 ¥6.36 ¥4.75 76
ROIC Compounder ¥2.71 ¥2.92 ¥3.10 72
Growth Earnings
Growth-Adj P/E ¥3.68 ¥5.26 ¥6.84 68

Widest divergence: DCF Models (¥12.33) versus Dividend Discount (¥1.13). Highest evidence: Growth DCF (80).

Notify me when 688329 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 427M CNY
Revenue growth (YoY) -26.0%
Net margin 2.3%
Return on equity 1.3%
Free cash flow 70.7M CNY FY2025
P/E ratio 248.8
More key figures
Operating margin -55.2%
EPS (TTM) ¥0.0900
EPS growth (YoY) +213%
Net debt 52.4M CNY FY2025

Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 66/100

Of which business quality 66 · Market factors (momentum, volatility) 43

Profitability 30
Margins and returns on capital today
Quality Growth 95
Are margins and returns improving?
Cashflow 74
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 78
Disciplined investing over empire-building
Low Volatility 67
Calm price path (market factor)
Momentum 35
Price trend over the last 3–12 months (market factor)
52W Momentum 30
Distance to the 52-week high (market factor)
Net Issuance 80
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Suzhou Iron Technology CO.,LTD. engages in the provision of intelligent medical material management solutions in China and internationally. The company operates through three segments: Smart Pharmacy, Smart Ward, Smart Warehousing, and Pharmaceutical Information.

Full company description

Suzhou Iron Technology CO.,LTD. engages in the provision of intelligent medical material management solutions in China and internationally. The company operates through three segments: Smart Pharmacy, Smart Ward, Smart Warehousing, and Pharmaceutical Information. It offers drug storage and dispensing integration solutions; and automated manipulator dispensing, intelligent storage and retrieval, automated disassembly and repackaging, narcotic drugs dispensary, automated self-service medication dispensing, and automated blister medication dispensing systems, as well as narcotic drugs and category-psychotropic substances management machines. The company also provides intelligent medical supplies management cabinets, self-built building touchless sanitization systems, and hospital-wide integrated nursing solutions, as well as automatic packing machine for tablets and capsules, and integrated machine for medicine basket cleaning and disinfection. In addition, the company offers a software information management platform that provides medical services to various levels of medical institutions to establish a smart medical service system. Suzhou Iron Technology CO.,LTD. was founded in 2006 and is based in Suzhou, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Suzhou Iron Technology CO.,LTD. reported revenue of ¥452M in FY2025 versus ¥389M in FY2021, a compound +3.8%/yr. Reported net income was ¥18.9M in FY2025, compounding −33.3%/yr from FY2021.

Growth Quality 76/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
452M CNY
Latest YoY
+39.1%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−1.8%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.9%
Avg. growth/yr (9Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+11.9%
Revenue +3.8%/yr
FY21 ¥389M
FY22 ¥477M
FY23 ¥364M
FY24 ¥325M
FY25 ¥452M
Net income −33.3%/yr
FY21 ¥95.6M
FY22 ¥102M
FY23 ¥29.5M
FY24 −¥21.7M
FY25 ¥18.9M

688329 screens 74% overvalued. Compare with Intuitive Surgical, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Suzhou Iron Technology CO.,LTD. Fair Value". https://www.fairvalue-calculator.com/stock/688329

Peer Group

Medical Instruments & Supplies · 203 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 66 · Above median
Fair Value upside −74% · Bottom 25%
Return on equity (TTM) 1% · Below median
Return on assets 0% · Bottom 25%
Net margin (TTM) 2% · Below median
Operating margin (TTM) -55% · Bottom 25%
Revenue growth -26% · Bottom 25%
Debt / equity 0.04× · Lower than median

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 248.8× · Pricier than 75% of peers
P/B 2.21× · Pricier than median
P/S (TTM) 4.05× · Pricier than median
P/FCF 3.6× · Cheaper than median
EV/EBITDA 48.9× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 0 · sector 27
PAST 5 · sector 25
HEALTH 98 · sector 96
DIVIDEND 0 · sector 32

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.33 $150.04 -63%
EssilorLuxottica Société anonyme 1EL €172.45 €68.55 -60%
Medline Inc MDLN $41.11 $30.15 -27%
Becton, Dickinson and Company BDX $150.65 $103.53 -31%
Alcon Inc ALC $70.26 $39.78 -43%
ResMed Inc RMD $203.87 $187.89 -8%
West Pharmaceutical Services, Inc WST $353.71 $143.97 -59%
Straumann Holding STMN CHF 106.00 CHF 47.31 -55%
Sartorius Stedim Biotech S.A DIM €188.50 €51.16 -73%
Coloplast A/S COLOB kr 414.00 kr 382.22 -8%

Compare Suzhou Iron Technology CO.,LTD. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Suzhou Iron Technology CO.,LTD. (688329) overvalued or undervalued?
As of Jul 12, 2026, our model estimates a fair value of ¥5.26 versus a price of ¥19.99, about −74% (overvalued).
What is the fair value of 688329?
Our model-based fair value for Suzhou Iron Technology CO.,LTD. is ¥5.26 (as of Jul 12, 2026), built from audited fundamentals. The current price is ¥19.99.
What is the quality score of 688329?
Suzhou Iron Technology CO.,LTD. has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Suzhou Iron Technology CO.,LTD. (688329)?
Suzhou Iron Technology CO.,LTD. reported trailing-twelve-month revenue of about 427M CNY (latest available figure, as of Jul 12, 2026).
What is the net profit margin of 688329?
The net profit margin of Suzhou Iron Technology CO.,LTD. is about 2.3%, meaning it keeps roughly 2.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Suzhou Iron Technology CO.,LTD. and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.